Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Dec 9, 2021
- Accession no.
- 0001209191-21-068922
- Filed
- Dec 9, 2021
- Trade date
- Nov 21-Dec 7, 2021
- Filing delay
- 18 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions. Open-market sales total $405.4K. It was filed 18 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2021 | Class B Common Stock | GGiftDisposed | −1,100,000 | $0.00 | $0 | 8,217,883 | Direct | |
| Nov 21, 2021 | Class B Common Stock | GGiftAcquired | +550,000 | $0.00 | $0 | 550,000 | Indirect | |
| Nov 21, 2021 | Class B Common Stock | GGiftAcquired | +550,000 | $0.00 | $0 | 550,000 | Indirect | |
| Dec 7, 2021 | Class B Common Stock | SSaleDisposed | −15,467 | $20.43F2 | −$315,990.81 | 8,202,416 | Direct | |
| Dec 7, 2021 | Class B Common Stock | SSaleDisposed | −1,200 | $21.06F3 | −$25,272 | 8,201,216 | Direct | |
| Dec 7, 2021 | Class B Common Stock | SSaleDisposed | −3,025 | $20.49F4 | −$61,982.25 | 146,975 | Indirect | |
| Dec 7, 2021 | Class B Common Stock | SSaleDisposed | −100 | $21.07 | −$2,107 | 146,875 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.01 to $20.99 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.
- F3
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $21.02 to $21.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.
- F4
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.07 to $21.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.